Agilent Technologies : Q1'25 Results Presentation
A
Agilent Technologies
Q1 FY2025
Financial Results Overview
Agilent Q1 2025 Results
Revenue
Operating Margin
EPS
$1.68B
25.1%(2)
$1.31(2)
+1.4% reported
-70 basis points y/y
+2% y/y
+1.2% core(1)(2)
-1.4% FX, +1.6% M&A
Capital Allocation
$431M operating cash flow | $90M paid to purchase 0.6M shares | $97M invested in capex | $71M paid in dividends
Insights
The demand environment for capital equipment continued to improve in Q1. A strong reception to the recently launched Infinity III LC also helped to drive an increase in the volume and pace of customer conversations around new opportunities and existing fleet refresh.
Revenue in China was better than expected, led by a strong win-rate on tenders related to the national stimulus program.
PFAS testing continues to be in high demand - with Agilent's best-in-class PFAS workflow solutions growing 70%+ in the quarter.
2/26/2025
3
Q1'25 Financial Results Overview
Q1 Revenue by Geography, Product Type and Segment
Geography
Product Type
Segment
Americas
Europe
Consumables
Instruments
LDG
AMG
Services
27%
Informatics
20%
37%
39%
40%
63%
33%
41%
Asia Pacific
ACG
2/26/2025
4
Q1'25 Financial Results Overview
Q1 Revenue by End Market
Q1 Core Growth(1) Results by End Market
Academic &
Diagnostics &
Chemicals &
Environmental &
Pharma
Advanced
Food
Government
Clinical
Forensics
Materials
0%
-7%
+7%
-2%
+9%
+6%
Continued
Softness globally,
Strong low double
Growth in the rest of
Excellent
Strong demand for
improvement, with
anticipated slowdown
digit growth in the
the world is offset by
performance in the
PFAS testing is
low single digit
in US government
Americas offset
a high-teens decline
China stimulus
captured with
growth ex-China and
spending impacts
softer Asia results
in China that was
program drives
Agilent's best-in-
mid single digit
willingness of some
impacted by the
impacted by Lunar
significant growth in
class PFAS workflow
services growth
US customers to
timing impact of
New Year timing
China, fueling the
solutions to drive
offset by softer
spend
Lunar New Year
strong result during
growth
consumables
the quarter
Share of Agilent Revenue by End Market(2)
35%
Pharma
8%
Academic & Gov
14%
Diagnostics & Clinical
23%
Chemicals & Advanced Materials
10%
Food
10%
Environmental & Forensics
2/26/2025
5
Q1'25 Financial Results Overview
Q1 Results by Segment
Life Sciences and Diagnostics Markets Group
Revenue
Growth
Operating Margin
Insights
$647M
+4% Reported
18.1%(3)
Q1 revenue ahead of expectations on strong high single digit growth performance in LC &
+1% Core (1)(2)
-30 bps y/y
LCMS, supported by positive customer reception to the recently launched Infinity III LC
platform. Margins down slightly due to currency headwinds.
Applied Markets Group
Revenue
Growth
Operating Margin
Insights
$338M
-4% Reported
25.0%(3)
Delivers better than expected revenue versus a very challenging Q1'24 comparison,
-2% Core (1)(2)
-110 bps y/y
impacted by the timing of Lunar New Year. Strong performance in the China stimulus helps
to drive top line result.
Agilent CrossLab Group
Revenue
Growth
Operating Margin
Insights
$696M
+1% Reported
31.8%(3)
Revenue was in-line with expectations, with solid mid-single digit growth in Services,
+3% Core (1)(2)
-60 bps y/y
including high-single digit growth in contract revenue.
(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX. (2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided. (3) Presented on a non-GAAP basis.
2/26/2025
6
Q1'25 Financial Results Overview
Guidance and Forward-looking Considerations
Based on forecasted currency exchange rates
Q2 25 Guidance(1)
Low End
High End
FY 25 Guidance(1)
Low End
High End
Net Revenue ($M)
$1,610
$1,650
Net Revenue ($M)
$6,680
$6,760
Core Revenue Growth (2)
+2.5%
+5.0%
Core Revenue Growth (2)
+2.5%
+3.5%
-2.1% FX, +2.0% M&A
-1.9% FX, +2.0% to +2.2% M&A
includes ~+2% Lunar New Year impact
EPS
$1.25
$1.28
EPS
$5.54
$5.61
FY25 Financial Considerations
Net Interest + Other Income/Expense: $0M ($5M income for Q2)
Guidance assumes diluted share counts of 286M for Q2 and for the full year
Operating Cash Flow of $1.6-1.7B and CapEx of $0.45B
Shareholder Returns: $284M in dividends. Anti-dilutive share repurchases at a minimum.(3)
2/26/2025
7
Q1'25 Financial Results Overview
2/26/2025
8
Q1'25 Financial Results Overview
Disclaimer
Agilent Technologies Inc. published this content on February 26, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 26, 2025 at 22:07:12.694.